RU2017136863A3 - - Google Patents

Download PDF

Info

Publication number
RU2017136863A3
RU2017136863A3 RU2017136863A RU2017136863A RU2017136863A3 RU 2017136863 A3 RU2017136863 A3 RU 2017136863A3 RU 2017136863 A RU2017136863 A RU 2017136863A RU 2017136863 A RU2017136863 A RU 2017136863A RU 2017136863 A3 RU2017136863 A3 RU 2017136863A3
Authority
RU
Russia
Application number
RU2017136863A
Other languages
Russian (ru)
Other versions
RU2017136863A (ru
RU2718780C9 (ru
RU2718780C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017136863A publication Critical patent/RU2017136863A/ru
Publication of RU2017136863A3 publication Critical patent/RU2017136863A3/ru
Application granted granted Critical
Publication of RU2718780C2 publication Critical patent/RU2718780C2/ru
Publication of RU2718780C9 publication Critical patent/RU2718780C9/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017136863A 2015-04-17 2016-04-14 Способы лечения рака легкого RU2718780C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
US62/149,184 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (4)

Publication Number Publication Date
RU2017136863A RU2017136863A (ru) 2019-05-17
RU2017136863A3 true RU2017136863A3 (https=) 2019-08-21
RU2718780C2 RU2718780C2 (ru) 2020-04-14
RU2718780C9 RU2718780C9 (ru) 2020-07-08

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017136863A RU2718780C9 (ru) 2015-04-17 2016-04-14 Способы лечения рака легкого

Country Status (13)

Country Link
US (1) US20180125970A1 (https=)
EP (1) EP3283886B1 (https=)
JP (1) JP2018516244A (https=)
KR (1) KR20170137848A (https=)
CN (1) CN107624071A (https=)
AU (1) AU2016248222A1 (https=)
BR (1) BR112017022320A2 (https=)
CA (1) CA2983126A1 (https=)
IL (1) IL255079A0 (https=)
MX (1) MX2017013390A (https=)
RU (1) RU2718780C9 (https=)
SG (1) SG11201708546UA (https=)
WO (1) WO2016168440A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607444C (en) * 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
WO2015186823A1 (ja) * 2014-06-06 2015-12-10 協和発酵キリン株式会社 Folr1標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
EP3544999A1 (en) 2016-11-23 2019-10-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
AU2019236091B2 (en) 2018-03-13 2025-06-05 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
AU2019291307B2 (en) * 2018-06-18 2024-04-04 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
KR20240162086A (ko) * 2022-03-11 2024-11-14 아스트라제네카 아베 항-FRα 항체-약물 접합체 치료법에 대한 점수 산정 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CA2607444C (en) * 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
MX343607B (es) 2010-11-05 2016-11-11 Morphotek Inc Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
SI2731972T1 (en) * 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof

Also Published As

Publication number Publication date
SG11201708546UA (en) 2017-11-29
CA2983126A1 (en) 2016-10-20
RU2017136863A (ru) 2019-05-17
IL255079A0 (en) 2017-12-31
JP2018516244A (ja) 2018-06-21
WO2016168440A1 (en) 2016-10-20
BR112017022320A2 (en) 2018-07-24
CN107624071A (zh) 2018-01-23
AU2016248222A1 (en) 2017-11-09
EP3283886B1 (en) 2020-01-15
MX2017013390A (es) 2018-06-13
RU2718780C9 (ru) 2020-07-08
RU2718780C2 (ru) 2020-04-14
EP3283886A1 (en) 2018-02-21
KR20170137848A (ko) 2017-12-13
US20180125970A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
BR122019018152A2 (https=)
RU2017136863A3 (https=)
BR112018002682A2 (https=)
AU2022228198B1 (https=)
BR112018003420A2 (https=)
BE2015C047I2 (https=)
BE2015C044I2 (https=)
BR0009349B1 (https=)
BR0007487B1 (https=)
CN303063429S (https=)
BR0001684B1 (https=)
BR0001536B1 (https=)
BR0002033B1 (https=)
CN303064884S (https=)
CN303064885S (https=)
BR0000763F1 (https=)
BR0108495B1 (https=)
BR0009994B1 (https=)
BR0009942B1 (https=)
BR0009761B1 (https=)
BR0009757B1 (https=)
BR0009717B1 (https=)
BR0009649B1 (https=)
BR0009373B1 (https=)
BR0007672B1 (https=)

Legal Events

Date Code Title Description
TH4A Reissue of patent specification
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210415